Free Trial
NASDAQ:GANX

Gain Therapeutics (GANX) Stock Price, News & Analysis

Gain Therapeutics logo
$1.48 -0.01 (-0.67%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$1.57 +0.09 (+6.08%)
As of 08/8/2025 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Gain Therapeutics Stock (NASDAQ:GANX)

Key Stats

Today's Range
$1.46
$1.53
50-Day Range
$1.44
$2.01
52-Week Range
$0.89
$3.19
Volume
133,249 shs
Average Volume
288,671 shs
Market Capitalization
$44.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.20
Consensus Rating
Buy

Company Overview

Gain Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

GANX MarketRank™: 

Gain Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 337th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Gain Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Gain Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Gain Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Gain Therapeutics are expected to grow in the coming year, from ($1.00) to ($0.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Gain Therapeutics is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Gain Therapeutics is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Gain Therapeutics has a P/B Ratio of 5.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Gain Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.60% of the float of Gain Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Gain Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Gain Therapeutics has recently decreased by 21.14%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Gain Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Gain Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.60% of the float of Gain Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Gain Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Gain Therapeutics has recently decreased by 21.14%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Gain Therapeutics has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Gain Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    4 people have searched for GANX on MarketBeat in the last 30 days.
  • MarketBeat Follows

    2 people have added Gain Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Gain Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.18% of the stock of Gain Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 11.97% of the stock of Gain Therapeutics is held by institutions.

  • Read more about Gain Therapeutics' insider trading history.
Receive GANX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gain Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GANX Stock News Headlines

Brokerages Set Gain Therapeutics, Inc. (NASDAQ:GANX) PT at $8.20
[No Brainer Gold Play]: “Show me a better investment.”
A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
Gain Therapeutics Announces Proposed Public Offering
See More Headlines

GANX Stock Analysis - Frequently Asked Questions

Gain Therapeutics' stock was trading at $2.16 at the start of the year. Since then, GANX shares have decreased by 31.5% and is now trading at $1.48.

Gain Therapeutics, Inc. (NASDAQ:GANX) issued its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.16).

Gain Therapeutics (GANX) raised $40 million in an initial public offering on Thursday, March 18th 2021. The company issued 3,600,000 shares at $10.00-$12.00 per share. BTIG and Oppenheimer & Co,. acted as the underwriters for the IPO and National Securities Corp. was co-manager.

Gain Therapeutics' top institutional investors include Geode Capital Management LLC (0.97%). Insiders that own company stock include Khalid Islam, Jeffrey Scott Riley, Gene Mack and Matthias Alder.
View institutional ownership trends
.

Shares of GANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Gain Therapeutics investors own include PayPal (PYPL), Pfizer (PFE), SEA (SE), Taiwan Semiconductor Manufacturing (TSM), ZIM Integrated Shipping Services (ZIM), ADC Therapeutics (ADCT) and Avino Silver & Gold Mines (ASM).

Company Calendar

Last Earnings
5/14/2025
Today
8/10/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GANX
CIK
1819411
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$12.00
Low Price Target
$6.00
Potential Upside/Downside
+454.1%
Consensus Rating
Buy
Rating Score (0-4)
3.17
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.86)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$20.41 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-247.55%
Return on Assets
-146.06%

Debt

Debt-to-Equity Ratio
0.05
Current Ratio
2.22
Quick Ratio
2.22

Sales & Book Value

Annual Sales
$50 thousand
Price / Sales
890.07
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.28 per share
Price / Book
5.29

Miscellaneous

Outstanding Shares
30,070,000
Free Float
27,911,000
Market Cap
$44.50 million
Optionable
Optionable
Beta
0.10
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:GANX) was last updated on 8/10/2025 by MarketBeat.com Staff
From Our Partners